Brief: Northwest Biotherapeutics provides update about phase 3 trial of Dcvax-L
08/12/2016 19:04
Dec 8 (Reuters) - Northwest Biotherapeutics Inc:
* NW Bio provides update about phase 3 trial of Dcvax-L for
newly diagnosed glioblastoma multiforme brain cancer
* Company announced that 331 of planned 348 patients have
been enrolled in phase 3 trial of Dcvax-L
* As a result of partial hold, trial has not enrolled last
17 of total 348 patients
* Since summer of last year, trial has been subject to a
partial clinical hold, only on recruitment
Source text for Eikon: ID:nPn1jN052a
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB